Stock Research Monitor: PCRX, SCYX, and MDCO
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on MYL sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. All you have to do is sign up today for this free limited time offer by clicking the link below.
On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares. The stock ended at $39.63, rising 1.07% from the last trading session. The Company's shares have gained 0.10% over the past year. The stock is trading above its 200-day moving average by 3.14%. Furthermore, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have a Relative Strength Index (RSI) of 55.42.
On May 14th, 2018, Mylan and West Virginia University announced a ten-year collaboration, supported by a $5 million charitable contribution from the former, to develop and implement a program that will expose children across West Virginia to STEM (Science, Technology, Engineering and Math) and challenge traditional thinking about how STEM skills can be applied. Get the full research report on MYL for free by clicking below at:
Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock finished yesterday's session 2.64% higher at $34.95 with a total trading volume of 499,701 shares. The Company's shares have gained 14.40% over the previous three months. The stock is trading above its 50-day moving average by 5.35%. Furthermore, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 55.08.
On May 03rd, 2018, Pacira Pharma announced its consolidated financial results for Q1 ended March 31st, 2018. Total operating expenses were $81.5 million in Q1 2018, GAAP net loss was $10.7 million, and non-GAAP net income was $0.9 million. The Company ended the quarter with cash, cash equivalents, short-term and long-term investments of $361.5 million. The free technical report on PCRX can be accessed at:
At the close of trading on Wednesday, shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. climbed 1.92%, ending the day at $1.59. The stock recorded a trading volume of 315,740 shares. The Company's shares have advanced 27.27% in the last month. The stock is trading 18.60% above its 50-day moving average. Moreover, shares of SCYNEXIS, which develops and commercializes anti-infectives to address unmet therapeutic needs, have an RSI of 65.19.
On May 01st, 2018, SCYNEXIS announced that the US FDA has granted both Qualified Infectious Disease Product and Fast Track designations for the oral formulation of SCY-078, the Company's novel oral and intravenous antifungal agent for the treatment of vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC. The Company also announced that it has completed enrollment in the Phase-2b, dose-finding study of oral SCY-078 for the treatment of VVC (the DOVE study), with release of top-line data expected by July 2018. Sign up for free on Wall St. Equities and claim the latest report on SCYX at:
Parsippany, New Jersey-based The Medicines Co.'s shares ended the day 0.99% higher at $31.64 with a total trading volume of 372,185 shares. The stock has gained 9.07% in the last month and 6.07% over the previous three months. The Company's shares are trading 1.61% above their 50-day moving average. Additionally, shares of Medicines Co., which provides medicines to treat acute and intensive care patients, have an RSI of 53.70.
On May 07th, 2018, Medicines Co. announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase-II study were presented at the 86th European Atherosclerosis Society Congress and accepted for publication in Circulation, the journal of the American Heart Association. See the free research coverage on MDCO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities